Nanobac Pharmaceuticals Inc. (OTCBB: NNBP) - Wednesday's shares increased 12.61% to $0.1340 per share with a total of 2,401,522 shares traded. On Sept. 12, 2006, Nanobac Pharmaceuticals, Inc. announced the release of an analytical profile on the Company, by respected micro-cap analyst Mr. Paul Silver, Director of Research for Wall Street Resources, Inc., which contains a short-term target value for NNBP of $0.91 per share. "We are very excited that Wall Street Resources has seen fit to issue an overall evaluation of our company, and with a short-term target value of $0.91 per share. Our management team and scientists have worked very hard to become the leader in Calcifying Nanoparticles (CNPs), and we consider this report to be verification that our management team is on track," stated John Stanton, CEO of Nanobac Pharmaceuticals. "The quality of Mr. Silver's research, coupled with the comprehensive analysis of our business plan, will assist the Company in gaining proper awareness among key decision makers in the market and help our investors and potential shareholders obtain a more thorough understanding of Nanobac Pharmceuticals, Inc." Mr. Silver stated, "Nanobac's extensive body of scientific research in the study of Calcifying Nanoparticles represents a paradigm shift in the understanding of calcific disease. We believe that Nanobac's developments of diagnostic and therapeutic products will revolutionize the medical industry. With the market for calcific diseases currently exceeding $500 billion per year, we believe that the commercial opportunities for Nanobac's products are virtually limitless."
Nanobac Pharmaceuticals, Incorporated, a bio-lifescience company, engages in the research and development of therapeutic and diagnostic technologies related to nanobacterium sanguineum. It also offers two diagnostic assays to identify the presence of Nanobacteria in blood, including NANO-CAPTURE for measuring levels of Nanobacterial antigen; and NANO-SERO for testing whether a patient has been exposed to Nanobacteria. Additionally, the company conducts biomedical research and clinical studies in the development of chronic prostatitis, kidney stones, and polycystic kidney diseases. Nanobac was co-founded by Neva Ciftcioglu in 1994. The company is headquartered in Tampa, Florida. |
